All News

Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

Taylor Watterson, PharmD, PhD, discusses several different ways pharmacy technician contributions can be better recognized and appreciated.

Check out our coverage from the American Pharmacists Association Annual Meeting and Exposition 2025!

Researchers explored pharmacists’ ability to collaborate with other health care professionals in single-disciplinary outpatient practice environments.

Taylor Watterson, PharmD, PhD, discusses the primary contributors to stress or frustration among pharmacy technicians and how to fix them.

Researchers reviewed current understandings of the role vaccines play in dermatology, what gaps persist, and what future research is necessary.

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.

Researchers conducted a narrative review to explore the possibility of integrating social perspectives and aspects into dermatological care and research.

Investigators of a study used a systematic review and meta-analysis to evaluate the risk of major adverse cardiac events related to cannabis by using real-world data.

Louisiana opened the investigation upon discovering a CVS text message campaign sent out to patients asking them to advocate against proposed legislation.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

The drug could also reduce chronic kidney disease when combined with insulin therapy.

The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.

In the study, the composition of the gut microbiome could also be affected by food insecurity, a known social determinant of health.

Researchers explored the incidence of pneumococcal hemolytic uremic syndrome in children living in Sweden from January 2009 to December 2024.

The review explored the “emerging” term gut-skin axis and aimed to decipher the bidirectional signaling of the skin and gastrointestinal tract during homeostatic and disease states.

The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.

Topline results from a phase 3 trial showed 64.1% of patients on atogepant achieved a 50% or greater reduction in mean monthly migraine days during months 4 to 6.

Real-world effectiveness data showed semaglutide reduced the risk of major kidney disease events by 26%.

Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.